FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 10/2021”.
The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of October 2021, we identify the following current VC trends in the US-Biotech sector:
- In 2021, overall Biotech funding in the USA has reached USD 27,678m so far
- Top 5 deals exceed USD 400m each, largest transaction amounted to USD 735m in Treeline Biosciences, Inc.
- Logos Capital (USA) leads the Top 5 Investors (by deal volume), followed by ARCH Venture Partners (USA) and OrbiMed (USA)
- Oncology dominates as the top indication
To access the full report, please click here.
By Dr. Mathias Schott, Sebastian Sommer and Alexander Kuhn